CML is a cancer of the white blood cells and it effects on average one individual in every
100,000. Since it was first described in 1845 by John Hughes Bennett and the subsequent …

Introduction: With the development of various BCR-ABL1 tyrosine kinase inhibitors (TKIs),
chronic myeloid leukemia (CML) has become a manageable hematologic malignancy and …

Chronic myeloid leukemia (CML) is a myeloproliferative disorder, characterized by a specific
chromosomal aberration, the Philadelphia [Ph] chromosome. The Ph chromosome is the …

Molecular monitoring of BCR-ABL transcript levels by real-time quantitative PCR is
increasingly being used to diagnose the disease and assess treatment response in patients …

Abstract 2284 Monitoring of CML is conventionally performed by RT-qPCR but the use of
RNA as the starting material leads to a number of disadvantages, which include propensity …

Molecular monitoring of chronic myeloid leukaemia (CML) patients by real time quantitative
reverse transcriptase PCR (RQ-PCR) is of clinical value, but the use of diverse laboratory …

Clinical papers frequently lack in-depth descriptions of analytical methods, triggering
possible doubts regarding their conclusions. Through this short communication, we would …

Quantitative competitive RT-PCR techniques have been developed to detect BCR-ABL
fusion transcripts in CML but they are hardly reproducible. In this work, we have developed …

The current first-line therapy of chronic myeloid leukemia (CML) is based on tyrosine kinase
inhibitors. Diagnostic kits that are capable of identifying at least a 4.5 log reduction in the …

Real-time quantitative reverse-transcription polymerase chain reaction (RQ-PCR) methods
for the quantitation of BCR-ABL mRNA in the blood of patients with chronic myeloid …